Novel recombinant anti-HER2/neu immunotoxin: Design and antitumor efficiency

E. A. Sokolova, T. A. Zdobnova, O. A. Stremovskiy, I. V. Balalaeva, S. M. Deyev

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)


The novel HER2/neu-specific recombinant immunotoxin 4D5scFv-PE40 consisting of 4D5scFv antibody (targeting module) and Pseudomonas exotoxin A fragment (effector module) combined in a single polypeptide chain via a flexible linker has been expressed and purified. This immunotoxin conserves specificity and affinity that are characteristics of the parental antibody 4D5scFv and exhibits selective and strong cytotoxic effect against cancer cells overexpressing HER2/neu receptor. The results of the experiments both in vitro (in cell cultures) and in vivo (in tumor-bearing animals) demonstrate high potential of 4D5scFv-PE40 for targeted therapy of tumors overexpressing HER2/neu.

Original languageEnglish
Pages (from-to)1376-1381
Number of pages6
JournalBiochemistry (Moscow)
Issue number12
Publication statusPublished - 13 Dec 2014
Externally publishedYes


  • 4D5scFv
  • Pseudomonas exotoxin A
  • receptor HER2/neu
  • recombinant immunotoxin
  • targeted therapy

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)

Fingerprint Dive into the research topics of 'Novel recombinant anti-HER2/neu immunotoxin: Design and antitumor efficiency'. Together they form a unique fingerprint.

Cite this